June 18, 2020
1 min read

Combination ophthalmic suspension for glaucoma launches in Japan

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A combination ophthalmic suspension designed to treat glaucoma and ocular hypertension has been launched in Japan, according to a press release.

Ailamide (brimonidine tartrate/brinzolamide) is the first combination ophthalmic suspension in Japan for the treatment of glaucoma and ocular hypertension that does not have beta-blockers. It was approved for use in March.

The drug is expected to improve patient adherence by replacing multidrug therapies. One drop is instilled in the eye twice daily.

Senju Pharmaceutical Co. is the marketing authorization holder of the drug, while collaborator Otsuka Pharmaceutical Co. “will conduct activities related to the provision of drug information,” the release said.